Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non–Small-Cell Lung Cancer

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00382 JCO Precision Oncology no. 6 (2022) e2200382. Published online December 1, 2022. PMID: 36455195 Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non–Small-Cell Lung Cancer Michael L. Cheng , MD1,2,3xMichael L. ChengSearch for articles by this author; Jessica K. Lee , MS4xJessica K. LeeSearch for articles by this author; Rachit Kumar, MD5xRachit KumarSearch for articles by this author; Harry Klein , PhD6xHarry KleinSearch for articles by this author; Kira Raskina , MD4xKira RaskinaSearch for articles by this author; Alexa B. Schrock , PhD4xAlexa B. SchrockSearch for articles by this author; Kesi S. Michael , BS1,7xKesi S. MichaelSearch for articles by this author; Tali Mazor , PhD6xTali MazorSearch for articles by this author; Ethan Cerami, PhD6xEthan CeramiSearch for articles by this author; Geoffrey R. Oxnard , MD4xGeoffrey R. OxnardSearch for articles by this author; David Liu , MD, MPH, MS2xDavid LiuSearch for articles by this author; Himisha Beltran , MD2xHimisha BeltranSearch for articles by this author; Lynette M. Sholl , MD8xLynette M. ShollSearch for articles by this author; Mizuki Nishino , MD, MPH9,10xMizuki NishinoSearch for articles by this author; and Pasi A. Jänne , MD, PhD1,2,11xPasi A. JänneSearch for articles by this author Show More 1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA2Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA3Present address: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA4Foundation Medicine, Cambridge, MA5Harold Alfond Center for Cancer Care, MaineHealth, Augusta, MA6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA7Present address: Foundation Medicine, Cambridge, MA8Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA9Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA10Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA11Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA https://doi.org/10.1200/PO.22.00382 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTM.L.C. was supported by a Conquer Cancer Foundation—American Society of Clinical Oncology Career Development Award.AUTHOR CONTRIBUTIONSConception and design: Michael L. Cheng, Mizuki Nishino, Pasi A. JänneProvision of study materials or patients: Rachit KumarCollection and assembly of data: Michael L. Cheng, Rachit Kumar, Kesi S Michael, Tali Mazor, Ethan Cerami, Lynette M. Sholl, Mizuki NishinoData analysis and interpretation: Michael L. Cheng, Jessica K. Lee, Harry Klein, Kira Raskina, Alexa B. Schrock, Ethan Cerami, Geoffrey R. Oxnard, David Liu, Himisha Beltran, Lynette M. Sholl, Mizuki NishinoManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael L. ChengHonoraria: Lynx Group, WebMD, Potomac Center for Medical EducationConsulting or Advisory Role: AstraZeneca, Inivata, Boehringer Ingelheim, Mirati TherapeuticsResearch Funding: Palleon Pharmaceuticals (Inst)Travel, Accommodations, Expenses: Daiichi Sankyo, AstraZeneca, GenzymeJessica K. LeeEmployment: Foundation MedicineStock and Other Ownership Interests: RocheKira RaskinaEmployment: Foundation MedicineStock and Other Ownership Interests: RocheResearch Funding: Foundation MedicineAlexa B. SchrockEmployment: Foundation MedicineStock and Other Ownership Interests: Foundation Medicine, RocheKesi S. MichaelEmployment: Foundation MedicineStock and Other Ownership Interests: Roche/GenentechEthan CeramiConsulting or Advisory Role: Third Rock VenturesGeoffrey R. OxnardEmployment: Foundation MedicineStock and Other Ownership Interests: RocheHimisha BeltranConsulting or Advisory Role: Janssen Oncology, AstraZeneca, Pfizer, Blue Earth Diagnostics, Foundation Medicine, Amgen, Loxo/LillyResearch Funding: Janssen (Inst), AbbVie/Stemcentrx (Inst), Bristol Myers Squibb Foundation (Inst)Travel, Accommodations, Expenses: Janssen OncologyLynette M. ShollStock and Other Ownership Interests: Moderna TherapeuticsConsulting or Advisory Role: Genentech (Inst), Lilly (Inst)Research Funding: Roche/Genentech (Inst)Mizuki NishinoConsulting or Advisory Role: Daiichi Sankyo, AstraZenecaResearch Funding: Toshiba (Inst), AstraZeneca (Inst), Daiichi Sankyo (Inst)Pasi A. JänneStock and Other Ownership Interests: Gatekeeper Pharmaceuticals, LoxoConsulting or Advisory Role: Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharma, Roche/Genentech, LOXO, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi Health Analytics, SFJ Pharmaceuticals Group, Sanofi, Daiichi Sankyo, Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar Biotech, TranscentaResearch Funding: AstraZeneca, Astellas Pharma, Daiichi Sankyo, Lilly, Boehringer Ingelheim, Puma Biotechnology, Takeda, Revolution MedicinesPatents, Royalties, Other Intellectual Property: I am a coinventor on a DFCI-owned patent on EGFR mutations licensed to Lab Corp. I receive postmarketing royalties from this inventionNo other potential conflicts of interest were reported.